Digoxin oral solution Rx
Generic Name and Formulations:
Digoxin 0.05mg; per mL; lime-flavored; contains alcohol 10%.
Roxane Laboratories, Inc.
Indications for Digoxin oral solution:
Mild-to-moderate heart failure (with a diuretic and an ACE inhibitor when possible). Control of ventricular response rate in chronic atrial fibrillation.
Individualize: see literature. Initially 0.003mg/kg per day. Monitor digoxin levels.
Individualize: see literature. >2yrs: initially 0.01mg/kg per day. Monitor digoxin levels.
Renal dysfunction: reduce dose. Sinus node disease. Incomplete AV block. Accessory AV pathway (Wolff-Parkinson-White syndrome). Heart failure with preserved LV ejection fraction (eg, restrictive cardiomyopathy, constrictive pericarditis, amyloid heart disease, acute cor pulmonale, hypertrophic cardiomyopathy). Electrical cardioversion. Acute MI. Toxicity risk increased by hypokalemia, hypomagnesemia, hypercalcemia, diabetes. Hypocalcemia may nullify effects. Thyroid disease. Hypermetabolic states. Monitor digoxin levels, electrolytes, renal function. Elderly. Children. Infants. Pregnancy (Cat.C). Nursing mothers.
May be potentiated by antiarrhythmics (amiodarone, propafenone, quinidine), calcium channel blockers (verapamil, diltiazem, nifedipine, nitrendipine), captopril, telmisartan, spironolactone, carvedilol, epoprostenol, diclofenac, indomethacin, tramadol, ketoconazole, itraconazole, rabeprazole, clarithromycin. May be antagonized by rifampin, acarbose, miglitol, cyclosporine, colestipol, St. John's Wort, albuterol. Increased risk of arrhythmias with sympathomimetics. Others (see literature).
GI upset, anorexia, CNS effects (eg, blurred or yellow vision, or mental disturbances, confusion, headache, weakness, dizziness, apathy), gynecomastia, rash, heart block, arrhythmias (esp. children).
- Limit Daily Use of Headphones, Warns WHO
- Sleep Deprivation Could Derail Healthy Eating Habits
- Not Enough COPD Patients Receiving Maintenance Tx, Research Suggests
- Harvoni for HCV Genotype 4, HIV Co-Infection Assessed in New Research
- Combo Therapy for HCV, HIV Co-Infection: New Data on Sustained Virologic Response